Navigation Links
Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Date:11/14/2007

Research has indicated that FlexNow(R) Joint Formula shows significant reductions in cartilage deterioration, joint inflammation, and joint pain.

EGG HARBOR TWP., N.J., Nov. 14 /PRNewswire/ -- BSP Pharma Inc., the maker and distributor of FlexNow(R) Joint Formula, has announced the findings from the new joint health clinical study completed this past June at the Australian Centre for Complementary Medicine Education and Research (ACCMER) in Brisbane, Australia led by Dr. Phillip Cheras PhD.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071114/NEW031 )

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/flexnow/29883/

Results show that, for those with elevated cartilage deterioration in their joints, FlexNow Joint Formula provides an unprecedented reduction in cartilage deterioration for a natural product, 44% higher than that reported for glucosamine.(1) This is the first human clinical study of a natural product showing such a great reduction in a well recognised marker for cartilage deterioration as well as significant reductions in joint specific inflammation and joint pain.

FlexNow is an all natural dietary supplement made with one ingredient, an extract from the shea nut which contains one of the most powerful inflammation fighters of any known plant. The ability of shea extract to reduce inflammation in the human body has only recently been discovered.

Dr. Cheras' was asked to be the principal investigator due to his ground breaking research showing it is highly likely that most joint problems are a vascular condition. Prior to this study, research had indicated that FlexNow had a strong ability to address this cause, and not just the symptoms of joint health.

"FlexNow shows great promise and BSP's approach to bringing this product to market is a model for responsible development for complementary medicine," said Cheras.

The research was designed to bring together a large number of previous studies, to confirm the efficacy of shea extract in humans and to further demonstrate the safety of FlexNow. FlexNow is one of only 7 dietary supplements to be accepted by the FDA in 2004 as meeting all safety requirements, which was further shown during the clinical study when there was no difference in adverse effects between FlexNow and placebo.

The biggest clinical surprise was the unprecedented reduction in the breakdown of cartilage, both compared to placebo and for that reported for glucosamine. The other remarkable findings were the strong reduction in inflammatory markers that are produced more in unhealthy joints and joint cartilage than normal joints, and high sensitivity C-reactive protein (hsCRP), which has been found to be higher in patients with unhealthy joints than controls.

"This clinical confirmation that FlexNow is significantly reducing cartilage breakdown and inflammation, gives us insight into why so many FlexNow Joint Formula users are telling us of their joint relief for the first time," said Leonard P. Smith, CEO and President, BSP Pharma Inc., "which is allowing so many people with joint pain to once again lead an active life."

The clinical study is being submitted for publication. Prior clinical studies can be found by visiting http://www.flexnow.us

(1) Christgau S, Henrotin Y, Tanko LB, et al. Osteoarthritic patients with

high cartilage turnover show increased responsiveness to the cartilage

protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004;

22:36-42.


'/>"/>
SOURCE BSP Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Tampa, FL (PRWEB) , ... February 17, 2017 ... ... a premier sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 ... through Wednesday, Inspirata will showcase its anatomic and molecular pathology workflow solution, as ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in the greater ... LifeNet 4 Families organization. , For more than 30 years, LifeNet 4 ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
(Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... , Feb. 17, 2017   Parker ... protecting the rights of victims injured by medical ... regulators to call for better reporting. Congress required ... Safety concerns involving power morcellators and duodenoscopes ... to investigate how hospitals report injuries and deaths ...
(Date:2/17/2017)... February 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, ... The global ablation technologies market is expected to grow at a ... The market is expected to grow at a CAGR of 9.5% ... 2016, and $9.05bn in 2026. ... How this report will benefit you Read on ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
Breaking Medicine Technology: